Physician Highlight
 Dr. Thomas C. Lee
Director of the Retina Institute, Dr. Lee specializes in retinopathy of prematurity and retinoblastoma, along with other challenging retinal diseases.
“As we work to provide solutions to retinal diseases, we are inspired by the chance to save the vision of a child who would otherwise go blind."
Read his Bio
Meet the Retina Institute Team
|
The Retina Institute in The Vision Center at Children's Hospital Los Angeles is committed to providing you and your child with the finest care and support services available. The award-winning physicians offer exceptional medical care, clinical research, advances in new treatments and technologies that improve patient outcomes.
Within the Retina Institute, lies the unique and specialized Retinoblastoma Progam, directed by Dr. A. Linn Murphree, which focuses on early diagnoses and treatment of the potentially fatal eye cancer.
Dr. Thomas C. Lee and Dr. A. Linn Murphree, together offer decades of experience in complex retinal disorders and are conducting influential research into these challenging pediatric eye conditions. They also are on the faculty at the Keck School of Medicine of the University of Southern California and attending physicians at Doheny Eye Institute.
Conditions we commonly provide care for include:
Video Footage about Retinopathy of Prematurity
Retina Institute Research
Our commitment to research in the Retina Institute has led to the development of new knowledge about retinoblastoma, retinopathy of prematurity and other disorders and new solutions for the children affected by them. There is much more to learn.
Basic research in the laboratory and clinical research involving human subjects carry the same purpose: to test scientific ideas or potential treatments. Not all research will help individual patients. But with each question we ask, we seek answers that will create the next step in understanding and addressing these complex diseases.
Clinical Trials
BLOCK ROP
This trial will examine the safety of using Bevacizumab (Avastin) to treat children with aggressive ROP that is failing despite laster treatment. This drug targets the growth factor (Vascular Endothelial Growth Factor - VEGF) that is responsible for causing the abnormal blood vessel growth in children with ROP. For more information (click here)
Inter-Institutional Comparison of ROP Incidence
This study will examine factors that contribute to the rate of ROP and determine whether specific neonatal practice patterns can reduce the frequency of ROP in very low birthweight premature children.
ROP in the Micropreemie
This study will characterize the rate of ROP in children born at 23 - 24 weeks gestation. Very little is known about this patient population or their risk of ROP. The study will also address whether these children have a poorer response rate to traditional laser therapy.
ROP SPEED
This study will compare the ability of an ROP screener to evaluate ROP based on a physical in-person exam versus examining a digital fundus photograph. This will help identify the most effective and efficient method for ROP screening.
To find recent publications by our team members, please refer to the bios below:
|